FIRST CHECK MULTI DRUG CUP 7 FOR MARIJUANA (THC), COCAINE (COC), AMPHETAMINE (AMP), METHAMPHETAMINE (MET), ECSTASY
Applicant
Worldwide Medical, LLC
Product Code
DKZ · Clinical Toxicology
Decision Date
Sep 7, 2005
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 862.3100
Device Class
Class 2
Indications for Use
The First Check® Multi Drug Cup 7 for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Ecstasy (MDMA), Opiates (OPI) and Phencyclidine (PCP) is a screening test for the rapid detection of one to seven of the above listed drugs in a variety of combinations in human urine. The designated cut-off concentrations of these drugs are as follows: Marijuana at 50 ng/ml, Cocaine at 300 ng/ml, Amphetamine at 1000 ng/ml, Methamphetamine at 1000 ng/ml, Ecstasy at 500 ng/ml, Opiates at 2000 ng/ml, and Phencyclidine at 25 ng/ml. This device provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. The test is intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing of the second step in the process, along with the materials for shipping the urine specimen to the laboratory, is provided.
Device Story
Device is a two-piece plastic cup with integrated test strips for qualitative detection of drugs of abuse in urine. User collects urine sample in cup; secures lid; rests cup on side to activate lateral flow immunoassay. Principle: competitive binding; drug-positive samples inhibit colored line formation; drug-negative samples produce colored line. Procedural control line confirms test validity. Intended for OTC home use by consumers. Preliminary positive results require confirmation via GC/MS; device includes materials for mailing samples to laboratory for confirmation. Benefits: provides consumers with rapid, preliminary information regarding drug presence/absence in urine.
Clinical Evidence
Consumer study with 240 untrained participants; 2,605 total assays performed using spiked urine samples (THC, COC, AMP, MET, MDMA, OPI, PCP) at concentrations ranging from 0% to 200% of cutoff. Overall interpretation accuracy was 98.7% (2,572/2,605). Incorrect interpretations occurred only within ±25% of the cutoff. Labeling effectiveness evaluated via questionnaire; 97.1% found test easy to run/read.
Technological Characteristics
One-step rapid chromatographic immunoassay. Principle: competitive binding of antibody/target drug complexes. Visual readout. No electronic components, software, or external energy source. Standalone test cup.
Indications for Use
Indicated for OTC rapid qualitative screening of human urine for presence of Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Ecstasy (MDMA), Opiates (OPI), and Phencyclidine (PCP). Intended for use by consumers (e.g., parents) as a preliminary test; requires confirmatory testing (e.g., GC/MS) for definitive results.
Regulatory Classification
Identification
An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.
Special Controls
*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
Ameditech Immutest Drug Screen Cup (k040092)
ImmuTest Multi-Drug Screen Panel II (k042975)
Submission Summary (Full Text)
{0}
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
DEVICE ONLY TEMPLATE
A. 510(k) Number:
k051966
B. Purpose of the Submission:
New device
C. Analyte:
Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Ecstasy (MDMA), Opiates (OPI) and Phencyclidine (PCP)
D. Type of Test:
Qualitative Lateral Flow Immunochromatographic Test
E. Applicant:
Worldwide Medical LLC
F. Proprietary and Established Names:
First Check Multi Drug Cup 7 for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Ecstasy (MDMA), Opiates (OPI) and Phencyclidine (PCP)
G. Regulatory Information:
1. Regulation section:
21 CFR 862.3100, Enzyme Immunoassay, Amphetamine
21 CFR 862.3870, Enzyme Immunoassay, Cannabinoids
21 CFR 862.3250, Enzyme Immunoassay, Cocaine and Cocaine Metabolites
21 CFR 862.3610, Thin Layer Chromatography, Methamphetamine
21 CFR 862.3650, Enzyme Immunoassay, Opiates
Unclassified, Enzyme Immunoassay, Phencyclidine
2. Classification:
Class II
3. Product Codes:
DKZ, LDJ, DIO, LAF, DJG and LCM
4. Panel:
Toxicology (91)
H. Intended Use:
1. Intended use(s):
Refer to the Indications for use below.
{1}
2. Indication(s) for use:
The First Check Multi Drug Cup 7 for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Ecstasy (MDMA), Opiates (OPI) and Phencyclidine (PCP) is a screening test for the rapid detection of one to seven of the above listed drugs in a variety of combinations in urine. The designated cut-off concentration of these drugs are as follows: Marijuana at 50 ng/mL, Cocaine at 300 ng/mL, Amphetamine at 1,000 ng/mL, Methamphetamine at 1,000 ng/mL, Ecstasy at 500 ng/mL, Opiates at 2,000 ng/mL, and Phencyclidine at 25 ng/mL. The test is intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample.
A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.
3. Special condition for use statement(s):
The First Check Multi Drug Cup 7 test provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/Mass spectrometry is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.
This assay is for OTC use.
The materials necessary for the confirmatory test are provided with the screening device. Materials, as well as the confirmatory test, are provided to the consumer at no additional cost. The consumer pays for shipment of the sample to the laboratory.
4. Special instrument Requirements:
Not applicable.
I. Device Description:
The device is a two piece plastic cup consisting of a plastic specimen collection cup and a plastic lid with between one and seven test strips sealed in plastic housing which is attached to the underside of the lid. To perform the test, you collect a urine sample with the collection cup provided. Secure the test list lid onto the specimen collection cup and rest the cup on its side to activate testing. The product also
{2}
includes an instruction booklet, a numbered sticker for confidential confirmation testing, a transportation pouch and a pre-addressed mailing box.
## J. Substantial Equivalence Information:
1. Predicate device name:
Ameditech Immutest Drug Screen Cup/ImmuTest Multi-Drug Screen Panel II
2. Predicate K numbers:
k040092/k042975
3. Comparison with predicate:
This device and the predicates are identical in product design, performance characteristics, materials, manufacturing, matrix used and are intended for use as an initial screening method subject to confirmation. The proposed device is intended to be sold over-the-counter (OTC) while the predicate devices are intended for prescription use only.
## K. Standard/Guidance Document Referenced (if applicable):
The sponsor did not reference any standards or guidance documents in their premarket submission.
## L. Test Principle:
This device uses a one step, rapid chromatographic immunoassay which operates under the principle of recognition and formation of specific antibody/target drug complexes. A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region if the test has been performed properly. If a control line does not appear for any reason, the results are considered invalid and should not be interpreted. The sample should either be retested using a new First Check Multi Drug Cup 7 or the sample should be mailed in for confirmation.
## M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Performance Characteristics have been addressed in k040092 and k042975 (Ameditech Immutest Drug Screen Cup and Ameditech ImmuTest Multi-Drug Screen Panel II).
b. Linearity/assay reportable range:
Not applicable
c. Traceability (controls, calibrators, or method):
{3}
The device has an internal procedural control; a colored line will always appear at the control line region if the test has been performed properly. The labeling informs users to check that the test is working properly by looking for a red or pink line next to the word control on all test strips. If a control line does not appear for any reason, the results are considered invalid and should not be interpreted. The sample should either be retested using a new First Check Multi Drug Cup 7 or the sample should be mailed in for confirmation.
d. Detection limit:
Performance Characteristics have been addressed in k040092 and k042975 (Ameditech Immutest Drug Screen Cup and Ameditech ImmuTest Multi-Drug Screen Panel II).
e. Analytical specificity:
Performance Characteristics have been addressed in k040092 and k042975 (Ameditech Immutest Drug Screen Cup and Ameditech ImmuTest Multi-Drug Screen Panel II).
f. Analytical specificity:
Performance Characteristics have been addressed in k040092 and k042975 (Ameditech Immutest Drug Screen Cup and Ameditech ImmuTest Multi-Drug Screen Panel II).
g. Assay cut-off:
The identified cutoff concentrations are those recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA). Analytical performance of the device around the cutoff is described in the precision section above.
2. Comparison studies:
a. Method comparison with predicate device:
Performance Characteristics have been addressed in k040092 and k042975 (Ameditech Immutest Drug Screen Cup and Ameditech ImmuTest Multi-Drug Screen Panel II).
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical sensitivity:
Not applicable
b. Clinical specificity:
Not applicable.
{4}
c. Other clinical supportive data (when a and b are not applicable): The accuracy and precision of the test was demonstrated in a study performed by 240 untrained users. 375 unique tests with sample solutions containing methamphetamine, morphine, phencyclidine, amphetamine, MDMA and benzoylecgonine were performed by consumers using drug-free urine that had been spiked with various concentrations and combinations of drugs. 355 unique tests with sample solutions containing THC were performed by consumers using drug-free urine that had been spiked with various concentrations and combinations of drugs. A total of 2,605 assays were performed. Each drug was tested at 0%, 50%, 75%, 125%, 150%, and 200% of the target concentration. Some samples contained as many as four drugs; there were samples that contained no drugs at all. Drug concentrations were confirmed by GC/MS at a SAMHSA laboratory; recovery ranged between 88.9% to 130.6% of the target concentration. Approximately 2.5% of the consumers had used a home drug kit before. 90% reported they were high-school graduates and the ratio of female to male was approximately 2:1. The study was conducted at three different locations (Phoenix, AZ; Johnson City, NY; and Bemidji, MN).
The results of the study are summarized below:
| DRUG | Cutoff Concentration (ng/ml) | Number of Studies | Correctly Interpreted | Incorrectly Interpreted |
| --- | --- | --- | --- | --- |
| THC | 50 | 355 | 353 | 2 |
| COC | 300 | 375 | 366 | 9 |
| AMP | 1000 | 375 | 373 | 2 |
| MET | 1000 | 375 | 372 | 3 |
| MDMA | 500 | 375 | 364 | 11 |
| OPI | 2000 | 375 | 369 | 6 |
| PCP | 25 | 375 | 375 | - |
2572 of 2605 tests were interpreted correctly (98.7%). All samples that were interpreted incorrectly were within ±25% of the cutoff value (75% or 125% of cutoff).
A consumer questionnaire was administered to evaluate labeling effectiveness. The following questions were asked: "Was the test easy to run and were the results easy to read?" and "Does it matter how light or dark the colored line is?". Seven participants (2.9%) answered that the test was not easy to run and the results were not
{5}
easy to read. Fifteen participants (6.25%) answered that it does matter how light or how dark the colored line is.
4. Clinical cut-off: Not applicable.
5. Expected values/Reference range: Not applicable.
**N. Proposed Labeling:**
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
**O. Conclusion:**
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.
